FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease

The autoinjector, branded as Leqembi Iqlik, contains a 360 mg/1.8 mL dose administered over 15 seconds. It is expected to enhance Alzheimer treatment accessibility and offer cost savings for patients.